20 July 2015
Strategia Therapeutics Forms Oncology/Hematology Medical Advisory Board
BOSTON–(BUSINESS WIRE) – Strategia Therapeutics, Inc. (Strategia) is an innovative pharmaceutical R&D company that provides strategy, management and optimization of global drug development programs with a new model for collaborative drug development by bringing together small, specific global expert teams for each drug project. Strategia announced today the formation of its first oncology/hematology Medical Advisory Board (MAB) to provide strategic medical/scientific advice and counsel to the Strategia board of directors and senior management team. The oncology/hematology MAB is comprised of three recognized oncology/hematology experts from leading academic facilities and research institutions. All three individuals have devoted their time and medical expertise to improving the lives of people afflicted with cancer and hematologic malignancies.
The three member board, chaired by Dr. Daniel D. Von Hoff, includes:
Daniel D. Von Hoff, MD, FACP, Physician in Chief, Distinguished Professor at TGen (Translational Genomics Research Institute) in Phoenix, Arizona, Chief Scientific Officer for US Oncology Research and for Honor Health’s Clinical Research Institute, Professor of Medicine, Mayo Clinic, Scottsdale, AZ. He and his colleagues were involved in the initial development of mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, nab-paclitaxel, vismodegib and others. Dr. Von Hoff is an internationally recognized expert in pancreatic cancer. Dr. Von Hoff has published more than 620 papers, 137 book chapters and over 1050 abstracts. He received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization).
Alan F. List, MD, President and Chief Executive Officer of Moffitt Cancer Center in Tampa, FL. Dr. List is internationally recognized as an expert in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical approval. Dr. List previously served as Executive Vice President and Physician-in-Chief, Vice Deputy Physician-in-Chief, and Chief of the Malignant Hematology Division at Moffitt, where he holds the Morsani Endowed Chair. He is the author of more than 300 peer-reviewed articles and the Clinician’s Manual on Myelodysplastic Syndromes (2008).
Alex A. Adjei, MD, PhD, FACP, Professor of Oncology and Chair of the Department of Medicine as well as Senior Vice-President for Clinical Research at the Roswell Park Cancer Institute (RPCI) in Buffalo, NY, the Katherine Anne Gioia Chair in Cancer Medicine at RPCI, Professor of Medicine and an Academic Scholar in Medicine at the State University of New York in Buffalo. Dr Adjei has served as chair or vice-chair in a number of US National Cancer Institute committees. He is currently the co-chair of the Thoracic Malignancies Steering Committee. He is the Editor-in-Chief of the Journal of Thoracic Oncology and a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC). He has a long track record in experimental therapeutics and early phase oncology drug development. He received the first ASCO Drug Development Research Professorship in 2012. He has authored 227 publications dealing primarily with preclinical pharmacology, phase I trials and novel therapeutics/phase II trials of lung cancer.
“I am glad to see the Strategia team pursuing some agents which have already demonstrated anticancer activity in their initial Phase 1 trials. Those leads need to be followed”, said Dr. Daniel D. Von Hoff, MAB Chair.
“Strategia Therapeutics’ patient-focused approach to new therapy development is extraordinary and is complimented by a breadth of exciting agents in their pipeline,” Dr. Alan F. List stated.
“It is a distinct pleasure to be a member of the Strategia oncology/hematology MAB,” Dr. Alex A. Adjei stated; “Strategia’s new drug development approach and vision is truly refreshing, as it places patient benefit as the primary focus of all decision-making. I am honored to contribute to what Strategia is trying to do for patients.”
“The medical/scientific advice and guidance provided by these 3 experts will assist Strategia in properly selecting and executing the development of novel agents for patients. In addition, it will further support the mission of Strategia Therapeutics: to help patients in need by accelerating the research and development of high quality, clinically viable drugs for truly unmet needs.” says Thomas Myers, MD, FACP, Chief Medical Officer of Strategia.
Together, Strategia and the Medical Advisory Board believe that they can change the future of the pharmaceutical industry with a new model for effective drug research and development for patients and their providers.
About Strategia Therapeutics, Inc. (Strategia)
Strategia is an innovative pharmaceutical R&D company with experience in developing, managing and optimizing global drug development programs. Its mission is to create a new model for collaborative drug development by bringing together small, global expert teams, each of which has expertise specific to a single drug. By focusing its efforts in this way, Strategia rapidly and successfully moves each project forward to completion while keeping internal infrastructure small and streamlined.